The company's core activity is the development, manufacture and marketing of biopharmaceutical products, including active pharmaceutical ingredients (APIs), vaccines and finished dosage forms (FDFs), as well as the production of biotechnological medicines for the manufacture of monoclonal antibodies and vaccines.
AI-generated
Offering
Products & services
Industry:Pharmaceutical Industry
✓ Offered4
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Biosimilar development for oncology, hematology, osteoporosis and pediatrics; research and development, cell line development, formulation development, analytical development and regulatory support.
Biologics CDMO Services
Biologics CDMO services from cell line development to bulk drug substance; tech transfer, process development, analytical development, formulation, validation, cGMP manufacturing and quality and regulatory affairs.
Manufacturing of Biosimilars and Biologics
Manufacturing of biosimilars and other biologic products at GMP sites in Europe and South America, including clinical and commercial batches, single-use systems and large cell culture capacity.
Biopharma R&D and Regulatory Support
In-house R&D with end-to-end development capabilities, internal IP and regulatory teams, scientific submissions and regulatory interactions worldwide.
Knowledge
No knowledge articles yet
Once MABXIENCE SA has claimed this profile, we'll publish editorial articles and case studies here together.